CETP and metabolic dysfunction-associated steatohepatitis: To further assess the therapeutic potential of HSP763-01, future studies should consider models that induce progressive, mild fibrosis over a longer duration, such as the AMLN diet62 or genetically modified models that more closely mimic human NASH pathology (e.g., CETP deficiency).63-65 Additionally, evaluating HSP763-01’s pharmacokinetic profile in mice will be essential to optimize dosing strategies for sustained therapeutic effects.